Table 1 Characteristics of CVOTs included in the meta-analysis
Study drug/mean follow-up (years) | Participants (n) | Age, mean or median (years) | Male sex (n, %) | Primary outcome | |
|---|---|---|---|---|---|
EMPA-REG 2015 | Empagliflozin 3.1 | 7020 | 61.3 | 5016 71.5 | MACE |
CANVAS 2017 | Canagliflozin 2.4 | 10,142 | 63.3 | 6509 64.2% | MACE |
DECLARE 2019 | Dapagliflozin 4.2 | 17,160 | 63.9 | 10,738 62.6% | MACE |
CREDENCE 2019 | Canagliflozin 2.6 | 4401 | 63.0 | 2907 66.1% | Composite renal: ESKD, doubling of serum creatinine levels, death from renal or CV causes |
DAPA-HF 2019 | Dapagliflozin 1.5 | 4744 | 66.0 | 3131 66.0% | Composite of worsening HF or CV death |
DAPA CKD 2020 | Dapagliflozin 2.4 | 4304 | 61.8 | 2879 66.9% | Composite renal: decline eGFR ≥ 50%, ESKD, death from CV or renal causes |
VERTIS-CV 2020 | Ertugliflozin 3.0 | 8246 | 64.4 | 5769 70.0% | MACE |
EMPEROR-R 2020 | Empagliflozin 1.5 | 3730 | 66.8 | 2837 76.0% | Composite of CV death and hospitalization for HF |
SCORED 2021 | Sotagliflozin 1.5 | 10,584 | 69.0 | 5896 55.7% | Composite of CV death, hospitalization for HF, urgent HT for HF |
SOLOIST-WHF 2021 | Sotagliflozin 0.75 | 1222 | 70.0 | 810 66.3% | Composite of CV death, hospitalization for HF, urgent HT for HF |
EMPEROR-P 2021 | Empagliflozin 2.2 | 5988 | 71.9 | 3317 55.4% | Composite of CV death and hospitalization for HF |